GI Innovation, Inc. (KOSDAQ:358570)

Market Cap	695.31B -20.2%
Revenue (ttm)	5.63B +2,550.4%
Net Income	-34.65B
EPS	-550.10
Shares Out	64.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	607,607
Open	10,900
Previous Close	10,820
Day's Range	10,790 - 12,030
52-Week Range	10,080 - 24,900
Beta	0.69
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 358570

Financial Performance

In 2025, GI Innovation's revenue was 5.84 billion, an increase of 23943.39% compared to the previous year's 24.28 million. Losses were -35.13 billion, -40.23% less than in 2024.